| DIRECT COMPETITOR COMPARISON | |
| ABT | MRK | RHHBY.PK | SNY | Industry | | Market Cap: | 84.08B | 76.75B | N/A | 102.25B | 128.20M | | Employees: | 69,000 | 55,200 | N/A | 98,213 | 181 | | Qtrly Rev Growth (yoy): | 3.50% | 1.80% | N/A | 8.50% | 14.60% | | Revenue (ttm): | 29.92B | 23.37B | N/A | N/A | 31.21M | | Gross Margin (ttm): | 58.31% | 76.36% | N/A | 75.20% | 72.39% | | EBITDA (ttm): | 8.64B | 7.81B | N/A | N/A | -1.66M | | Oper Margins (ttm): | 22.32% | 26.63% | N/A | N/A | 2.37% | | Net Income (ttm): | 5.60B | 8.05B | N/A | N/A | N/A | | EPS (ttm): | 3.691 | 3.808 | N/A | N/A | N/A | | P/E (ttm): | 14.73 | 9.56 | N/A | N/A | 13.69 | | PEG (5 yr expected): | 1.28 | 2.09 | 1.37 | 2.54 | 2.11 | | P/S (ttm): | 2.80 | 3.27 | N/A | N/A | 3.29 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.47 | 1.18% | 58.17B | 12.53 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.53 | 0.32% | 13.75B | 15.91 | | Genzyme Corp. | GENZ | 50.97 | 1.17% | 13.53B | 29.06 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.9001 | -0.13% | 42.21B | 18.14 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.56 | 0.76% | 9.02B | 1031.84 | | Teva Pharmaceutical Industries Limited | TEVA | 53.32 | 0.09% | 46.97B | 48.78 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.61 | 1.51% | 3.99B | 19.39 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.12 | 0.33% | 3.01B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.3319 | 0.17% | 5.60B | 112.47 | | Pfizer Inc. | PFE | 18.4095 | 0.54% | 148.56B | 15.29 | | Johnson & Johnson | JNJ | 63.155 | -0.04% | 174.25B | 13.79 | | GlaxoSmithKline plc | GSK | 42.70 | 0.99% | 108.24B | 13.43 | | Sanofi-Aventis | SNY | 39.158 | 1.37% | 102.25B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.72 | 0.76% | 126.55B | 16.68 | | RHHBY.PK | 42.02 | 1.38% | N/A | N/A | | AstraZeneca plc | AZN | 46.18 | 2.06% | 66.96B | 9.27 | | Abbott Laboratories | ABT | 54.36 | 0.22% | 84.08B | 14.73 | | Bristol-Myers Squibb Co. | BMY | 25.61 | 1.79% | 50.73B | 13.25 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | SNY | | Sanofi Expands Regeneron Agreement
Wed 10:10am -
Zacks.com | | • | MRK | | Three Reasons Merck's Time Has Come
Wed 10:05am -
at Minyanville.com | | • | SNY | | Worse Than The NBC-Comcast Deal? No Deal
Wed 9:58am -
at Forbes.com | | • | SNY | | Making Flu Vaccine: Eggs Aren't the Only Problem
Wed 8:43am -
at The Wall Street Journal Online | | • | RHHBY.PK | | Inhibition of Cell Migration by Gene Silencing - Measured with the xCELLigence Cell Analysis System from Roche
Wed 8:00am -
Business Wire | | • | MRK | | Merck's Relief in Texas
Wed 7:58am -
Zacks.com | | • | MRK | | Merck Serono to Spend $225 Million on New Beijing R&D Center
Wed 7:09am -
at Seeking Alpha | | • | MRK | | The World's Best Dividend Stocks
Wed 7:00am -
at Motley Fool | | • | MRK | | [$$] Bears' Bets Up at NYSE, Nasdaq
Tue 7:19pm -
at The Wall Street Journal Online | | • | MRK | | Forgetful patients lift support consultancies
Tue 6:05pm -
at FT.com | | • | SNY | | Cramer's 'Mad Money' Follow-Up: Nov. 24
Tue 5:23pm -
at TheStreet.com | | • | MRK | | Merck to buy back up to $3 billion in stock
Tue 5:02pm -
at MarketWatch | | • | SNY | | How Big Pharma Profits from Swine Flu
Tue 3:37pm -
at BusinessWeek | | • | SNY | | Novartis Teams Up With the US for Vaccines
Tue 3:15pm -
at Minyanville.com | | • | SNY | | Novartis 'Cells' Its Flu Vaccine Technology
Tue 12:52pm -
at CNBC | | • | SNY | | Cramer's Lightning Round: Sensational Ciena (11/23/09)
Tue 6:51am -
at Seeking Alpha | | • | SNY | | Lightning Round: AT&T, Verizon, Novartis and More
Mon, Nov 23 -
at CNBC | | • | SNY | | 'Mad Money Lightning Round': Ciena's a Bargain
Mon, Nov 23 -
at TheStreet.com | | • | RHHBY.PK | | Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Mon, Nov 23 -
PR Newswire | | • | RHHBY.PK | | Spectrum Pharma: Zevalin Sales Ramp Up
Sun, Nov 22 -
at Seeking Alpha | | • | RHHBY.PK | | Desktop Bug Detector
Fri, Nov 20 -
at Forbes.com | | • | RHHBY.PK | | Biotech Stocks: Senate bill weighs on Allergan, Medicis
Thu, Nov 19 -
at MarketWatch | | • | RHHBY.PK | | 454 Life Sciences Unveils New Bench Top Sequencer, Significant Improvements to the Genome Sequencer FLX System Including 1,000 bp Reads for 2010
Thu, Nov 19 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
0.26% Nasdaq 
Competitors
